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High-sensitivity C-reactive protein predicts
cardiovascular events and myocardial damage after
vascular surgery
Domenico Scrutinio, MD,a Andrea Passantino, MD,a Francesca Di Serio, MD,b Domenico Angiletta,
MD,c Daniela Santoro, MD,a and Guido Regina, MD,c Bari, Italy
Objective: To assess the association of high-sensitivity C-reactive protein (hsCRP) to adverse cardiovascular events and
perioperative myocardial damage in patients after elective vascular surgery.
Methods: This was a prospective observational study in a tertiary-care teaching hospital, with 239 patients undergoing
elective vascular surgery. The receiver-operating characteristic (ROC) curve was calculated to assess the optimal cut-off
value of hsCRP. Odds ratios (ORs) with 95% confidence intervals (CIs) were calculated. Multiple logistic regression
analysis was used to identify the predictors of the primary outcome. The primary outcome was a composite of
periprocedural myocardial damage, defined as cardiac troponin I (cTn-I) elevation above the decision limit of 0.15g/L,
death, acute coronary syndrome, stroke, acute heart failure, or intrastent thrombosis within 30 days of surgery.
Results: On ROC analysis, the optimal cut-off value of hsCRP was 3.2 mg/L. The primary outcome occurred in 48
patients (20.1%). On univariate analysis, smoking (P  .009), known hypercholesterolemia (P  .01), previous ischemic
heart disease (P  .0003), open surgery (P  .03), and hsCRP levels (P < .0001) were associated with the primary
outcome. On multiple logistic regression analysis, only hsCRP was independently associated with the primary outcome.
The unadjusted and adjusted ORs for the primary outcome among patients with hsCRP levels>3.2 mg/L were 7.5 (CI,
3.7-15.2; P < .0001) and 4.6 (CI, 2.1-9.9; P  .0001), respectively.
Conclusion: Our data suggest that higher levels of hsCRP are independently associated with an increased risk of
perioperative myocardial damage and early adverse cardiovascular events in patients undergoing elective vascular surgery.
This may have implications for risk stratification and therapeutic approach. (J Vasc Surg 2011;54:474-9.)
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UVascular surgery has long been associated with a high
risk.1 An incidence of postoperative myocardial damage
and cardiac events in the range of 11% to 47% and 2% to
10%, respectively, has been reported.2-6 As cardiac scoring
systems have a limited discriminative value for the predic-
tion of major adverse cardiovascular events in vascular
surgery,7 there is increasing interest in the use of biomark-
ers as predictors of adverse outcomes.
Vascular inflammation plays a fundamental role in
atherothrombosis,8 contributing to the onset and progres-
sion of atherosclerotic lesions, to plaque instability and
related clinical events.9 There is evidence that high sensi-
tivity C-reactive protein (hsCRP), a leading inflammatory
biomarker for clinical application,10 is independently asso-
ciated with the risk of incident or recurring cardiovascular
events, regardless of the lipid levels.11 Moreover, although
a continuing controversy exists regarding whether C-reac-
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474ive protein (CRP) is only a marker or whether it may also
lay a causal role in the atherothrombotic process,12,13
ome interventional studies suggest that lowering CRP
evels by statin therapy may translate into improved out-
ome regardless of the resultant level of LDL cholester-
l,14-16 thus supporting the concept that hsCRP possibly
ontributes to drive thrombotic complications of athero-
clerosis. Elevated hsCRP levels have also been related to
he occurrence of adverse medium-term cardiovascular
vents after vascular surgery.17,18 A few studies also suggest
hat elevated levels of hsCRP are independently associated
ith a higher risk of early cardiac events and myocardial
njury among patients undergoing noncardiac vascular sur-
ery.19,20
While the role of hsCRP is of pathophysiological, clin-
cal, and, potentially, therapeutic interest, it has not been
ufficiently investigated as a predictor of adverse cardiovas-
ular outcomes after vascular surgery. In this study, we
ought to assess the relation of hsCRP to early adverse
ardiovascular events and myocardial damage in patients
ndergoing elective vascular surgery.
ETHODS
Study design. This was a prospectively designed obser-
ational study. The study population consisted of 239 patients
ndergoing elective carotid or peripheral lower extremity
evascularization or aortic surgery at the Vascular Surgery
nit of theUniversity of Bari (Italy). Patients requiring emer-
ent vascular surgery were excluded. Exclusion criteria also
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Volume 54, Number 2 Scrutinio et al 475included cardiac troponin I (cTn-I) blood levels above the
upper reference limit on the preoperative day, acute limb
ischemia, current active infections (eg, pneumonia, genitouri-
nary tract infections), chronic inflammatory diseases, tumors,
or major surgery in the previous 6 months. Before surgery, all
patients underwent a routine clinical evaluation, including
detailed medical history, physical evaluation, routine labora-
tory tests, 12-lead electrocardiography, and chest radiogra-
phy. Additional non-invasive tests were performed at the
treating physician’s discretion. The presence of ischemic heart
disease was indicated by a previous myocardial infarction,
coronary intervention, or current angina pectoris. Patients
were closely monitored for in-hospital and 30-day clinical
events. A 12-lead electrocardiogram was recorded at 6, 12,
24, and 48 hours after the procedure. During hospitalization,
in case of signs and symptoms suggestive of myocardial isch-
emia, repeated cTn-I determinations and electrocardiography
were performed, and a cardiologist was consulted. Patients
experiencing events were transferred to the intensive care unit
at the discretion of the attending physician and/or the con-
sultant cardiologist. The study was approved by the local
Institutional Review Board.
Determination of biomarkers. Peripheral blood
samples for hsCRP measurement were obtained on the
preoperative day in all patients. The hsCRP level was mea-
sured using the commercially available Dimension RxL
immunoassay (Siemens Healthcare Diagnostics, Glasgow,
DE). Peripheral blood samples for cTn-I determination
were obtained on the preoperative and postoperative days 1
and 2 in all patients. cTn-I was measured using the Dimen-
sion RxL immunoassay; the limit of detection was 0.03
g/L, and the decision limit for myocardial damage was
0.15 g/L (coefficient of variation: 10%).
Outcome. The primary outcome was a composite of
periprocedural myocardial damage and death, acute coronary
syndrome, stroke, acute heart failure, or intrastent thrombosis
within 30 days of surgery. Acute coronary syndrome was
defined as ST-segment elevation myocardial infarction, non–
ST-segment elevation myocardial infarction, or unstable an-
gina. The diagnosis of myocardial infarction was made in
accordance with standard criteria.21 Unstable angina was de-
fined as ischemic chest pain associated with diagnostic ST-
segment and/or T-wave changes without a diagnostic eleva-
tion of biomarkers of myocardial injury. Periprocedural
myocardial damage was defined as a cTn-I increase above the
decision limit in at least one of the two postoperative samples.
Data analysis. Continuous variables are reported as
mean  standard deviation and categorical variables as per-
centages. Comparisons of baseline characteristics were per-
formedwith t test for continuous variables and Pearson 2 test
for categorical variables. The following variables were in-
cluded in the univariable analysis: age, gender, current smok-
ing, hypertension, diabetes mellitus, known hypercholesterol-
emia, history of cerebrovascular disease, previous ischemic
heart disease or heart failure, site of surgery (carotid, abdom-
inal aortic, or lower extremity), type of surgery (endovascular
or open procedure), hematocrit, hemoglobin, serum creati-
nine, fibrinogen, total cholesterol, and hsCRP. In order to gssess the optimal cut-off value of hsCRP for predicting
he primary outcome, the receiver-operating character-
stic (ROC) curve was calculated. The optimal cut-off
alue was defined as the concentration with the highest
um of sensitivity and specificity. On ROC analysis, the
ptimal cut-off value of hsCRP was 3.2 mg/L. At this
alue, hsCRP had a sensitivity and specificity of 54.2%
nd 86.4%, respectively. The area under the ROC curve
as 0.71 (standard error, 0.03; Fig 1). The other con-
inuous variables were dichotomized at their median
alue. Odds ratios (ORs) with 95% confidence intervals
CIs) were calculated. Variables with P  .10 at univar-
ate analysis were entered in the multiple stepwise logistic
egression analysis. P values of less than .05 from two-
ided tests were considered statistically significant. The
tatistical software package SPSS 8.0 (IBM Corp., Som-
rs, NY) was used.
ESULTS
The baseline characteristics are reported in Table I.
ean age was 70.4  9.7 years, and 79.9% were males. Of
he patients, 48.1% underwent carotid revascularization,
9.2% abdominal aortic surgery, 30.6% peripheral lower
xtremity revascularization, and 2.1% other vascular sur-
ery. Of the carotid patients, 27.8% had had a previous
erebrovascular event. An open or endovascular procedure
as performed in 42.7% and 57.3% of the patients, respec-
ively. Mean hsCRP was 2.57  4.02 mg/L. Fifty-two
atients (21.8%) had an hsCRP concentration3.2 mg/L.
he distribution of hsCRP values is shown in Fig 2. Mean
sCRP levels of the patients who underwent carotid or
eripheral lower extremity revascularization or aortic sur-
ig 1. Receiver-operating characteristic curve of high-sensitivity
-reactive protein levels to predict the primary outcome.ery were 1.65  2.63 mg/L, 4.03  5.24 mg/L (P 
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August 2011476 Scrutinio et al.0001), and 2.49  3.96 (P  NS), respectively. Mean
hsCRP levels of the patients who underwent endovascular
treatment or open surgery were 2.32  3.81 mg/L and
2.93  4.30 mg/L, respectively (P  NS). Forty-one
percent of the patients were on chronic statin therapy at
admission; their mean cholesterol level was not different
from that of the patients who were not on statin therapy
(211.9  41.4 mg/dL vs 211.4  40.8 mg/dL).
Forty-eight patients (20.1%) had an event within 30
days of surgery: two patients died (0.8%) (one patient died
of fatal myocardial infarction and one of fatal stroke), 12
had an acute coronary syndrome (5%; 11 myocardial infarc-
tions, one unstable angina), five acute heart failure (2.1%),
four a stroke (1.7%), two an intrastent thrombosis (0.8%),
and 23 periprocedural myocardial damage (9.6%; in 83% of
the cases, elevation in cTn-I was 3 times the decision
limit). Patients experiencing postoperative events had sig-
nificantly higher hsCRP levels than those who did not
(5.43  5.89 mg/L vs 1.85  3.02 mg/L, P  .0001;
Table I). The incidence of the primary outcome among
patients undergoing carotid revascularization, lower ex-
Table I. Baseline characteristics
Over
Male gender, n (%)
Age (years), mean (SD) 7
Hypertension, n (%)
Diabetes, n (%)
Smoking, n (%)
Known hypercholesterolemia, n (%)
Cerebrovascular events, n (%)
Previous ischemic heart disease, n (%)
Previous heart failure, n (%)
Previous vascular surgery, n (%)
Site of surgery
Carotid, n (%)
Lower extremity, n (%)
Abdominal aortic, n (%)
Other, n (%)
Type of surgery
Endovascular procedure, n (%)
Open procedure, n (%)
Leukocytes (103/L), mean (SD) 6
Hematocrit (%), mean (SD) 3
Hemoglobin (g/dL), mean (SD) 1
Serum creatinine (mg/dL), mean (SD) 1
Serum creatinine 2.0 mg/dL, n (%)
Fibrinogen, (mg/dL), mean (SD) 35
Total cholesterol (mg/dL), mean (SD) 20
hsCRP 3.2 mg/L, n (%)
hsCRP, (mg/L), mean (SD) 2
Therapy at admission:
Antiplatelets, n (%)
Warfarin, n (%)
Intravenous heparin, n (%)
Low-molecular-weight heparin, n (%)
Renin angiotensin aldosterone system inhibitors, n (%)
Beta-blockers, n (%)
Statins, n (%)
hsCRP, High-sensitivity C-reactive protein, SD, standard deviation.tremity revascularization, or abdominal aortic intervention aas 14.8%, 26.1% (P  .06), and 26.1% (P  NS), respec-
ively. The incidence of the primary outcome among pa-
ients undergoing open surgery or endovascular procedures
as 25.5% and 16.1% (PNS), respectively. The incidence
f the individual events according to the site and type of
urgical procedure is reported in Table II.
On univariable analysis, smoking, known hypercholes-
erolemia, previous ischemic heart disease, open surgery,
nd hsCRP levels were associated with the primary out-
ome (Table III). On multiple logistic regression analysis,
nly hsCRP was independently associated with the primary
utcome (Table III). The unadjusted and adjusted ORs for
he primary outcome among patients with hsCRP levels
3.2 mg/L were 7.5 (CI: 3.7-15.2; P  .0001) and 4.6
CI: 2.1-9.9; P .0001), respectively. In a further analysis,
he association between hsCRP and the composite end
oint of death, acute coronary syndrome, or periprocedural
yocardial damage was assessed. hsCRP remained inde-
endently associated with a higher risk of events. The
nadjusted and adjusted ORs among patients with hsCRP
evels 3.2 mg/L were 7.16 (CI, 3.31-15.51; P  .0001)
 239) No events (N  191) Events (N  48) P value
79.9) 149 (78) 41 (85.4) .347
9.7) 70.3 (10) 69.9 (8.5) .756
86.3) 126 (66) 44 (91.2) .0009
35) 63 (33) 21 (43.7) .219
55.8) 99 (51.8) 35 (72.9) .013
46.3) 78 (40.8) 32 (66.7) .002
17) 35 (18.3) 6 (12.5) .457
21.7) 35 (18.3) 23 (47.9) .0001
3.8) 6 (3.1) 3 (6.2) .557
30) 51 (26.7) 20 (41.7) .04
48.1) 98 (51.3) 17 (35.4) .07
30.6) 54 (28.3) 19 (39.6) .178
19.2) 34 (17.8) 12 (25.0) .354
2.1) 5 (2.6) -- --
57.3) 115 (60.2) 22 (45.8) .101
42.7) 76 (39.8) 26 (54.2) .106
2.12) 6.87 (2.17) 6.88 (1.96) .979
5.4) 37.1 (6.4) 35.0 (5.8) .039
2.0) 13.06 (1.9) 12.56 (1.8) .116
1.17) 1.19 (1.15) 1.32 (1.26) .496
6.7) 12 (6.3) 4 (8.3) .853
123) 346.5 (121.2) 391.3 (127.9) .024
45) 207.3 (46) 220 (40) .083
21.8) 26 (13.6) 26 (54.2) .0001
4.02) 1.85 (3.02) 5.43 (5.89) .0001
80.4) 151 (79) 43 (89.6) .144
4.6) 7 (3.7) 4 (8.3) .319
1.3) 3 (1.6) — —
0.8) 2 (1.0) — —
30.4) 59 (30.9) 14 (29.2) .955
27.2) 51 (26.7) 14 (29.2) .871
41) 75 (39.3) 23 (47.9) .354all (N
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In this prospective study, we assessed the association of
preoperative hsCRP with early adverse cardiovascular out-
comes in patients undergoing elective vascular surgery. Our
data suggest that higher hsCRP levels are strongly and inde-
pendently associated with the risk of myocardial damage and
early cardiovascular events following vascular surgery.
Vascular inflammation can contribute to atherothrom-
Fig 2. Distribution of hsCRP values in the overall popula
Table II. Incidence of the individual events and mean hsC
procedure
Site of surgery (N)
Endovascular
Number of
patients
Mean hsCRP
(mg/L) Event
Carotid (115) 63 1.3  2.2 Tn-I*
ACS
Strok
Lower extremity (73) 43 3.4  4.5 Tn-I*
ACS
AHF
I–S th
Abdominal (46) 30 2.6  4.4 Tn-I*
ACS
ACS, Acute coronary syndrome; AHF, acute heart failure; hsCRP, high-s
perioperative myocardial damage.bosis, plaque instability, and the genesis of acute athero- Ohrombotic events.8,9 hsCRP is a leading inflammatory
iomarker strongly associated with an increased risk of
ncident or recurring vascular events.10 In this study, one in
ve patients had an hsCRP concentration 3.2 mg/L.
ompared with patients with hsCRP levels 3.2 mg/L,
hey had a 4.6-fold increased adjusted risk of periproce-
ural myocardial damage and cardiovascular events within
0 days of surgery, regardless of type and site of surgery.
A) and according to the type (B) and site of surgery (C).
values according to the site and type of surgical
pe of surgical procedure
Open
N (%)
Number of
patients
Mean hsCRP
(mg/L) Events N (%)
(4.8)
(1.6)
(1.6)
52 2.1  3.0 Tn-I*
ACS
Stroke
AHF
I–S th
Death
3 (5.8)
3 (5.8)
3 (5.8)
1 (1.9)
1 (1.9)
1 (1.9)
(9.1)
(6.8)
(6.9)
(2.3)
30 4.9  6.0 Tn-I*
ACS
Death
5 (14.7)
2 (5.9)
1 (2.9)
(13.1)
(6.7)
16 2.6  4.0 Tn-I*
ACS
AHF
4 (25)
1 (6.2)
1 (6.2)
ity C-reactive protein; I–S th, intrastent thrombosis; N, number; Tn-I*,RP
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August 2011478 Scrutinio et alal19 where higher levels of hsCRP were independent pre-
dictors of postoperative cardiac events. After adjustment for
cardiac risk factors, site of surgery and type of procedure,
hsCRP levels 6.5 mg/dL were associated with a 2.5-fold
increased risk of postoperative cardiac events. Notably,
hsCRP improved risk stratification with cardiovascular risk
factors and type and site of procedure. Similar results were
obtained by Choi et al in a study of noncardiac surgery
patients, 25.9% of whom had undergone vascular sur-
gery.20 After adjustment for other risk predictors and tra-
ditional clinical risk factors, each one standard deviation
increase in hsCRP was associated with a 74% increased risk
of perioperative major cardiovascular events, and the pre-
dictive power of hs-CRP was also better than the clinical
risk score. Collectively, these findings suggest that hsCRP
measurement should be included in the current risk evalu-
ation systems in order to improve the effectiveness of risk
stratification of vascular surgery patients. Clinically, how-
ever, it should be recognized that risk evaluation based only
on hsCRP might be misleading as, despite a strong associ-
ation with outcome, the individual discriminative value of
hsCRP, as assessed by the area under the ROC curve, was
modest (about 0.70) by current convention22 in both the
present study and that of Goei et al.19 This, however, is not
surprising, as it is well known that risk stratification based
on any single prognostic factor, even though potent, has
limited prognostic accuracy in clinical practice.
Potential therapeutic implications. The finding that
higher levels of hsCRP are independently associated with
an increased risk of adverse outcome after vascular surgery
may have therapeutic implications.
Statin therapy is indicated for all patients with athero-
sclerotic disease, including candidates to vascular sur-
gery,1,23 because of its lipid-lowering effect. A growing
body of evidence also suggests the use of statins as an
anti-inflammatory intervention in atherosclerosis.10 When
targeting hsCRP, it should, however, be recognized that
the CRP-lowering effect of statins is largely independent
of that on lipoproteins.14 A minimal level of correlation
between statin therapy-induced reduction in low-density
lipoproteins and hsCRP levels has indeed been observed.23
Moreover, hsCRP response varies with dose for any given
statin,24 and high statin doses may be required to success-
fully reduce CRP levels.14,24 Intriguingly, in a prospective
observational study of 359 patients undergoing major vas-
Table III. Results of univariate and multivariate analyses
Unadjusted odds ratio
(Confidence intervals)
Smoking 2.5 (1.2-5.2)
Known hypercholesterolemia 2.9 (1.5-5.8)
Previous ischemic heart disease 3.5 (1.8-7.1)
Type of surgery 2.0 (1.04-3.7)
hsCRP 3.2 mg/L 7.5 (3.7-15.2)
hsCRP, High-sensitivity C-reactive protein.cular surgery, only higher statin doses were independently dssociated with lower myocardial ischemia, troponin T
elease, and 30-day and late cardiac events.25 Thus, it is
empting to speculate that screening elective vascular
urgery candidates for hsCRP, regardless of their actual
tatin therapy and lipid levels, and modulating the inten-
ity of statin therapy accordingly may be a reasonable
pproach for achieving both lipid reduction and CRP
eduction. Hopefully, this would also improve postoper-
tive clinical outcome. This hypothesis ought to be
ested in ad hoc designed clinical trials. Moreover, there
s suggestive evidence that acute loading with high statin
oses can lower CRP concentrations26 and be of clinical
enefit for patients undergoing percutaneous coronary
ntervention.16,27,28 In the Novel Approaches for Pre-
enting or Limiting Events (NAPLES) II trial,16 a single
reprocedural 80-mg loading dose of atorvastatin signif-
cantly decreased the incidence of periprocedural myo-
ardial infarction only in patients with elevated CRP, not
n those with normal CRP levels. Assessing whether
igh-dose statin loading prior to vascular surgery exerts
nti-inflammatory and cardioprotective effects might be
f special interest.
Limitations of the study. The data were collected
rom patients undergoing elective vascular surgery at a
ingle teaching hospital. Women were poorly represented.
he number of patients and clinical events was relatively
mall. Although our results are consistent with other pub-
ished studies,19,20 further studies are needed to confirm
he prognostic role of hsCRP in larger populations and
ssess the incremental value of hsCRP for risk stratification
n vascular surgery. We used a composite end point of
linical events and cTn-I elevation, which has nearly abso-
ute myocardial tissue specificity as well as high clinical
ensitivity.21 Although cTn-I accurately identifies myocar-
ial necrosis, it does not inform as to the cause or causes of
ecrosis.21 However, it should be considered that most
atients (90%) undergoing vascular procedures have cor-
nary artery disease,29 and that an association between a
igh incidence of minor troponin elevation and preopera-
ive coronary artery disease has been established.30 More-
ver, etiologies of cTn-I elevation other than myocardial
nfarction, such as aortic dissection, pulmonary embolism,
enal or respiratory failure, or sepsis, were not clinically
P value
Adjusted odds ratio
(Confidence intervals) P value
.009 —
.001 —
.0003 —
.03 —
.0001 4.6 (2.1-9.9) .0001iagnosed in our patients.
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Our data suggest that higher levels of hsCRP are inde-
pendently associated with an increased risk of periproce-
dural myocardial damage and early adverse cardiovascular
events in patients undergoing elective vascular surgery.
This may have implications for risk stratification and ther-
apeutic approach.
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